Aberdeen Group plc reduced its stake in Tempus AI, Inc. (NASDAQ:TEM – Free Report) by 16.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 213,294 shares of the company’s stock after selling 41,436 shares during the quarter. Aberdeen Group plc owned about 0.12% of Tempus AI worth $13,553,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently made changes to their positions in the stock. ARK Investment Management LLC boosted its position in shares of Tempus AI by 35.9% in the 1st quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company’s stock worth $361,867,000 after purchasing an additional 1,981,755 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Tempus AI by 6,247.5% during the 1st quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company’s stock valued at $289,204,000 after buying an additional 5,900,668 shares during the period. Nikko Asset Management Americas Inc. lifted its holdings in shares of Tempus AI by 31.5% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company’s stock valued at $205,401,000 after buying an additional 1,021,460 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Tempus AI by 31.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company’s stock valued at $205,284,000 after buying an additional 1,016,384 shares during the period. Finally, CloudAlpha Capital Management Limited Hong Kong bought a new position in shares of Tempus AI during the 1st quarter valued at $34,119,000. 24.22% of the stock is owned by institutional investors.
Tempus AI Trading Down 4.9%
NASDAQ:TEM opened at $89.87 on Wednesday. The company has a debt-to-equity ratio of 2.58, a current ratio of 1.54 and a quick ratio of 1.43. The firm has a market capitalization of $15.61 billion, a price-to-earnings ratio of -75.52 and a beta of 4.87. Tempus AI, Inc. has a one year low of $31.36 and a one year high of $104.32. The business has a fifty day moving average price of $80.27 and a 200-day moving average price of $65.36.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on TEM. Bank of America increased their price target on Tempus AI from $68.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, June 25th. Needham & Company LLC restated a “buy” rating and issued a $70.00 price objective on shares of Tempus AI in a research note on Friday, August 8th. BTIG Research upped their price objective on Tempus AI from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, August 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research note on Wednesday, October 8th. Finally, HC Wainwright upped their price objective on Tempus AI from $90.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $71.83.
View Our Latest Research Report on TEM
Insiders Place Their Bets
In other Tempus AI news, COO Ryan Fukushima sold 5,000 shares of the stock in a transaction on Monday, October 6th. The stock was sold at an average price of $92.32, for a total value of $461,600.00. Following the completion of the sale, the chief operating officer owned 130,000 shares in the company, valued at approximately $12,001,600. This represents a 3.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James William Rogers sold 7,528 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $561,965.20. Following the completion of the sale, the chief financial officer owned 138,473 shares of the company’s stock, valued at $10,337,009.45. The trade was a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 933,662 shares of company stock worth $68,070,993 in the last three months. 26.27% of the stock is owned by company insiders.
Tempus AI Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
- Five stocks we like better than Tempus AI
- Are Penny Stocks a Good Fit for Your Portfolio?
- After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
- What Are Dividend Achievers? An Introduction
- Buyback Boom: 3 Companies Betting Big on Themselves
- What is the Australian Securities Exchange (ASX)
- Analysts Flock to Upgrade DELL After Big AI-Server Guidance Boost
Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.